Efficacy of Three-Week Oxytetracycline or Rifampin Monotherapy Compared with a Combination Regimen against the Filarial Nematode Onchocerca ochengi by Bah, G. S. et al.
Efficacy of Three-Week Oxytetracycline or Rifampin Monotherapy
Compared with a Combination Regimen against the Filarial Nematode
Onchocerca ochengi
Germanus S. Bah,a,c Emma L. Ward,a Abhishek Srivastava,b* Alexander J. Trees,a,b Vincent N. Tanya,c Benjamin L. Makepeacea,b
Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdoma; Liverpool School of Tropical Medicine, Liverpool, United Kingdomb; Institut
de Recherche Agricole pour le Développement, Regional Centre of Wakwa, Ngaoundéré, Adamawa Region, Cameroonc
Onchocerciasis (river blindness), caused by the filarial nematodeOnchocerca volvulus, is a major cause of visual impairment and
dermatitis in sub-Saharan Africa. AsO. volvulus contains an obligatory bacterial symbiont (Wolbachia), it is susceptible to anti-
biotic chemotherapy, although current regimens are considered too prolonged for community-level control programs. The aim
of this study was to compare the efficacies of oxytetracycline and rifampin, administered separately or in combination, against a
close relative ofO. volvulus (Onchocerca ochengi) in cattle. Six animals per group were treated with continuous or intermittent
oxytetracycline regimens, and effects on adult worm viability, dermal microfilarial loads, andWolbachia density in worm tissues
were assessed. Subsequently, the efficacies of 3-week regimens of oxytetracycline and rifampin alone and a combination regimen
were compared, and rifampin levels in plasma and skin were quantified. A 6-month regimen of oxytetracycline with monthly
dosing was strongly adulticidal, while 3-week and 6-week regimens exhibited weaker adulticidal effects. However, all three regi-
mens achieved>2-log reductions in microfilarial load. In contrast, rifampinmonotherapy and oxytetracycline-rifampin duo-
therapy failed to induce substantive reductions in either adult worm burden or microfilarial load, although a borderline effect
onWolbachia density was observed following duotherapy. Dermal rifampin levels were maintained above theMIC for>24 h
after a single intravenous dose. We conclude that oxytetracycline-rifampin duotherapy is less efficacious againstO. ochengi than
oxytetracycline alone. Further studies will be required to determine whether rifampin reduces oxytetracycline bioavailability in
this system, as suggested by human studies using other tetracycline-rifampin combinations.
Onchocerciasis, or “river blindness,” is a vector-borne parasiticdisease that continues to affect 26 million people, predomi-
nantly in sub-Saharan Africa, despite 4 decades of concerted con-
trol efforts (1). The etiological agent, Onchocerca volvulus, is a
filarial worm that resides in subcutaneous nodules when mature
and has a life span of 10 years (2). Although the nodules are
generally benign, the female worm releases approximately 1,000
first-stage larvae (microfilariae [Mf]) per day (3), which accumu-
late in the skin and can induce severe pruritus and dermatitis.
After several years, the Mf can also migrate into the eyes, where
their death prompts local inflammatory reactions, visual impair-
ment, and, ultimately, irreversible blindness. Whereas the original
Onchocerciasis Control Programme was initially focused on vec-
tor control, the current African Programme for Onchocerciasis
Control (APOC) is almost entirely dependent on mass drug ad-
ministration (MDA) of the macrocyclic lactone ivermectin (4).
This strategy has been in place in many regions of endemicity for
approximately 2 decades and has been extremely successful in
preventing blindness and onchodermatitis (5), since ivermectin
rapidly clears Mf from the skin. Recent data have also demon-
strated that ivermectin can eliminate onchocerciasis in areas of
seasonal transmission (6), and this has led APOC to redefine itself
as an elimination program with a target attainment date of 2025
(4). However, ivermectin MDA faces a number of challenges that
may compromise the progress of APOC over the next decade.
These include severe adverse events following ivermectin treat-
ment in individuals heavily coinfected with Loa loa (a species of
filarial worm endemic to Central Africa) (7), continued transmis-
sion of onchocerciasis in perennial-transmission zones despite 15
to 18 years of MDA (8, 9), evidence of decreased ivermectin sus-
ceptibility in some worm populations (10, 11), variable compli-
ance with MDA within affected communities (12), and a lack of
adulticidal efficacy against the parasite (13).
Until relatively recently, no safe adulticidal drug for onchocer-
ciasis existed. This changed with the identification of Wolbachia
endobacteria (order Rickettsiales) in filariae of medical impor-
tance in the late 1990s (14, 15), which prompted a series of exper-
iments in animal models demonstrating that antibiotics (espe-
cially the tetracyclines) not only impede the growth and
embryogenesis of filarial worms (16, 17) but also can kill the adult
parasites (18). Such effects were not observed at clinically relevant
doses in filarial species that naturally lack Wolbachia symbionts
(16, 19). Clinical trials of doxycycline (DOX) for human on-
chocerciasis were implemented rapidly, which achieved steriliza-
tion of female worms using a regimen of 200 mg/day for 4 weeks
(20) or 100 mg/day for 5 weeks (21). However, significant adulti-
cidal activity (killing of 60 to 70% of female worms) required a
regimen of 200 mg/day for 6 weeks (20). This relatively protracted
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course of treatment, coupled with contraindications in children
below 8 years of age and in pregnant or lactating women, have
prevented approval of DOX for MDA to date; this is despite the
very high rates of compliance evident in a clinical trial that was
conducted in a region of Cameroon where loiasis is endemic (22).
Nevertheless, DOX has been applied in a small onchocerciasis
focus in Venezuela to expedite elimination efforts (23).
Experiments performed in vitro using isolated worms or
Wolbachia-infected cell lines (24–26), as well as in vivo trials in
rodent models (27, 28), have indicated that rifampin (RIF) is at
least as effective as the tetracyclines for symbiont depletion and,
indeed, may be superior. However, two human trials of RIF for
onchocerciasis failed to demonstrate that this bactericide could
truncate the therapeutic duration significantly, as a 5-day regimen
had no effect on either adult worms or microfilarial densities (29),
whereas 2-week and 4-week regimens induced a partial embryo-
static effect but were not adulticidal (30). Although these data
were equivocal, there remains the possibility that a combination
of a tetracycline and RIF substantially shortens the regimen re-
quired to achieve potent adulticidal effects.
A major challenge in onchocerciasis research is the inability of
Onchocerca spp. to complete their life cycles in rodent models.
However, in cattle, Onchocerca ochengi, which is the closest extant
relative ofO. volvulus (31), has been used extensively to investigate
drug efficacy for onchocerciasis, and numerous bovine studies
have displayed strong concordance with data obtained from hu-
man chemotherapeutic trials (18, 32, 33). Importantly, adult
worms of O. ochengi reside in intradermal nodules with a histo-
logical structure highly similar to that of O. volvulus, and the par-
asites are fertile for many years (34). Here, we use this natural
host-parasite system to determine whether the addition of RIF to
an oxytetracycline (OXY) regimen with limited activity against
adult worms can reduce the treatment duration for unequivocal
parasite killing to 3 weeks.
MATERIALS AND METHODS
Drugs. Oxytetracycline dihydrate was obtained as a commercially avail-
able, long-acting formulation (Terramycin LA, 200 mg/ml; Pfizer Animal
Health, Tadworth, United Kingdom) that is licensed for use in cattle. RIF
was kindly donated by Lupin Ltd. (Mumbai, India) in solid form as the
unformulated active pharmaceutical ingredient. For administration to
cattle, the powder was dissolved at 1% (wt/vol) in 25 mM HEPES buffer
(pH 7.0 to 7.6), 20% (vol/vol) dimethyl sulfoxide (DMSO) solvent (both
cell culture grade; Sigma-Aldrich, Gillingham, United Kingdom), and
sterile normal saline in intravenous bags. Prior to injection, the RIF solu-
tion was warmed to 37°C in an incubator to ensure complete dissolution
and was transported to the field protected from light.
Animals, chemotherapy, and sampling strategy. Zebu cattle
(Ngaoundéré Gudali breed), naturally infected with 20 palpable O.
ochengi nodules per animal, were purchased from markets across the Ad-
amawa Region of Cameroon (Vina Division) and assembled at the Institut
de Recherche Agricole pour le Développement (IRAD), Regional Centre
of Wakwa, where transmission of O. ochengi is negligible. The pretreat-
ment recording of nodule position and the randomization of animals into
treatment groups were performed as previously described (35). Evalua-
tions of antibiotic efficacy were conducted in two consecutive experi-
ments (Table 1); the first compared continuous 3-week or 6-week OXY
monotherapy (OXY3 and OXY6, respectively) with a prolonged intermit-
tent OXY regimen (PIR) (36), whereas the second was designed to deter-
mine whether a 3-week RIF-plus-OXY combination regimen (COM) was
superior to 3 weeks of RIF or OXY monotherapy. These experiments
utilized different animals, with the exception of two cows from the first
control (CON-1) group, which were reused in the second control
(CON-2) group. Four animals from experiment 1 and one animal from
experiment 2 died before the studies were completed (Tables 1 and 2)
from causes unrelated to either onchocerciasis or the drug treatments.
Two nodules per animal were removed under local anesthesia in a
randomized sequence at six predetermined time points, transferred to the
laboratory in phosphate-buffered saline (PBS), and trimmed of excess
tissue. One nodule was fixed by injection with 10% (vol/vol) neutral buff-
ered formalin, while the diameter of the other was measured with calipers
prior to parasitological analysis. Three superficial skin biopsy specimens
per animal were also obtained from the ventral underside at each time
point and transported to the laboratory in PBS for the determination of
Mf density.
Ethical considerations. This study was approved by the Ethics Com-
mittee of the Regional Centre of Wakwa, IRAD, and authorized by the
Regional Programmes Committee of IRAD. All procedures performed on
cattle in Cameroon were equivalent to those previously authorized by a
Home Office Project License (Animals [Scientific Procedures] Act, 1986)
for experimental infections of cattle in the United Kingdom and classified
under the severity limit “mild.”
Parasitology. Nodules were dissected in PBS, the male and female
worms were separated, and their motility was scored on a 3-point scale
after incubation at 37°C for 30 min as detailed previously (32). The Mf in
skin biopsy specimens were quantified and normalized to densities per
100 mg skin as described previously (32).
Immunohistochemistry and semiquantification of Wolbachia. For
experiment 2, the formalin-fixed nodules were embedded in paraffin and
4-m sections were probed with an anti-Wolbachia surface protein poly-
clonal antibody (kindly provided by M. Casiraghi, University of Milan,
Italy) using the universal LSAB2 horseradish peroxidase kit (Dako United
Kingdom Ltd., Ely, United Kingdom) as detailed previously (36). The
TABLE 1 Sample sizes and treatment regimens for experiments 1 and 2
Expt
Group
designation
Original group size
No. of animals
lost during
expt Treatment regimen (duration)aFemales Males
1 CON-1 6 0 1 None
1 PIR 6 0 1 OXY at 20 mg/kg i.m. once/mo (6 mo)
1 OXY3-1 6 0 0 OXY at 20 mg/kg i.m. twice/wk (3 wk)
1 OXY6 6 0 2 OXY at 20 mg/kg i.m. twice/wk (6 wk)
2 CON-2 6 0 1 DMSO at 220 mg/kg i.v. twice/wk (3 wk)
2 RIF3 5 1 0 RIF at 10 mg/kg i.v. and DMSO 220 mg/kg i.v. twice/wk (3 wk)
2 OXY3-2 6 0 0 OXY at 20 mg/kg i.m. twice/wk (3 wk)
2 COM 5 1 0 RIF at 10 mg/kg i.v., DMSO at 220 mg/kg i.v., and OXY at 20 mg/kg
i.m. twice/wk (3 wk)
a OXY, oxytetracycline; i.m., intramuscularly; DMSO, dimethyl sulfoxide; i.v., intravenously; RIF, rifampin.
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TABLE 2 Effect of oxytetracycline, rifampin, and a combination regimen on adult worms of Onchocerca ochengi in naturally infected cattle
Groupa Time (wpt)
No. of
cattle
No. of nodules
No. of worms per nodule
site (no. of viable worms
onlyb) in:
Median motility score
inc:
Intact Degeneratedd Males Females Males Females
CON-1 0 6 6 0 1.7 1.3 2 2
4 6 6 0 3.3 1.3 1 2
12 5 5 0 0.8 1.2 1.5 2
24 5 5 0 1.4 1.0 (0.8) 2 1
36 5 5 0 2.2 (2.0) 1.0 (0.8) 1 1
55 5 5 0 0.8 1.0 (0.8) 2 2
PIR 0 6 6 0 4 1.2 2 2
4 6 6 0 1.5 1.0 1 1.5
12 5 5 0 0.8 1.0 2 1
24 5 4 1 0.2 (1.0) 1.2 2 1
36 5 5 0 0.4 (0.0) 1.0 (0.2) 0 0
55e 5 2 3 0 0.4 (0.2) —f 1
OXY3-1 0 6 6 0 1.5 1.0 2 2
4 6 6 0 1.5 1.0 1 2
12 6 6 0 0.8 1.0 2 1.5
24 6 5 1 1.3 0.8 (0.7) 1 1
36 6 6 0 1.0 (0.3) 1.0 (0.2) 0 0
55 6 2 4 0.2 0.3 2 1
OXY6 0 6 6 0 1.5 1.2 2 2
4 6 6 0 1.7 1.0 (0.8) 2 1.5
12 4 4 0 2.0 1.0 2 2
24 4 4 0 3.0 (2.0) 1.3 (1.0) 1 1
36 4 4 0 0.3 1.0 (0.5) 1 0.5
55e 4 2 2 0 0.5 (0.3) —f 0.5
CON-2 0 6 6 0 0.8 1.0 2 2
4 6 6 0 1.2 1.0 2 2
12 6 6 0 1.5 1.0 2 2
24 6 6 0 1.5 1.0 (0.3) 2 0
36 6 5 1 1.5 0.8 2 2
52 5 5 0 1.8 1.0 2 2
OXY3-2 0 6 6 0 1.7 1.0 2 2
4 6 6 0 0.3 1.2 (1.0) 1.5 1
12 6 6 0 0.3 1.0 1.5 1
24 6 6 0 0.5 1.0 (0.7) 2 1
36 6 6 0 0.7 1.0 (0.8) 2 1
52e 6 6 0 0.3 1.0 (0.5) 1 0.5
RIF3 0 6 6 0 1.2 1.0 (0.8) 2 2
4 6 6 0 2.0 1.0 1 1
12 6 6 0 1.3 1.0 2 2
24 6 6 0 0.5 1.0 (0.8) 2 1
36 6 6 0 0.3 1.0 (0.5) 2 0.5
52 6 6 0 0.8 (0.5) 1.0 (0.8) 1 1
COM 0 6 6 0 0.8 1.0 2 1.5
4 6 6 0 1.3 1.0 2 2
12 6 6 0 0.5 1.0 2 2
24 6 6 0 1.3 1.0 (0.8) 2 1
36 6 5 1 1.0 0.8 1.5 2
52 6 6 0 0.3 1.0 (0.7) 1.5 2
a CON-1, no treatment; PIR, oxytetracycline once monthly for 6 months; OXY3-1 and OXY3-2, oxytetracycline twice weekly for 3 weeks; OXY6, oxytetracycline twice weekly for 6
weeks; CON-2, DMSO solvent only; RIF3, rifampin twice weekly for 3 weeks; COM; rifampin and oxytetracycline twice weekly for 3 weeks.
b Worms were considered viable where the motility score was1. Note that O. ochengi nodules normally contain a single female worm and a variable number of males (0 to10).
c Motility was scored on a 3-point scale after incubation of worms for 30 min at 37°C, as follows: 0, no movement; 1, sluggish movement; and 2, highly active.
d “Degenerated” refers to worm remnants only or fragmented nodules from skin biopsy specimens (in which fragmentation was too advanced to allow sexing and motility scoring).
e The total number of viable worms recovered at the end of the experiment was significantly reduced compared with the number in control animals (P 0.05).
f Data were missing due to the absence of male worms in all nodules.
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sections were counterstained with Giemsa stain, and digital images were
obtained on a Microphot-FX microscope (Nikon, Tokyo, Japan) using a
DCM900 microscope camera with imaging software (ScopeTek, Hang-
zhou, China). Wolbachia staining of worm sections across the entirety of
each slide was semiquantified on a 3-point scale, as follows: 0, no visible
bacteria; 1, sparse bacteria (50% of worm sections were positive); and 2,
profuse bacteria (50% of worm sections were positive).
Quantification of RIF in bovine plasma and skin. Four zebu cows
that were extraneous to experiments 1 and 2 and did not receive other
drugs were treated with a single dose of RIF at 10 mg/kg of body weight in
DMSO at 220 mg/kg. A plasma sample and triplicate superficial skin bi-
opsy specimens (mean weight,140 mg) were obtained from each animal
at 0, 1, 8, 24, 48, and 72 h after treatment and were stored at80°C. The
skin biopsy specimens were thawed, combined for each animal, and mac-
erated (protected from light) in 2 ml PBS using a T10 basic Ultra-Turrax
disperser (IKA, Staufen, Germany) with an 8-mm dispersing element. To
comply with the stipulations of a United Kingdom Department of Envi-
ronment, Food, and Rural Affairs import license, both the skin homoge-
nates and the plasma samples were heat inactivated at 56°C for 30 min
prior to transportation to the United Kingdom on dry ice. RIF was quan-
tified in the samples using a previously published liquid chromatograph-
ic-tandem mass spectrometric method with a lower limit of quantification
of 25 ng/ml (37). Calibration standards containing known amounts of
RIF (Sigma-Aldrich) were prepared separately in drug-free bovine plasma
and skin homogenates obtained from United Kingdom abattoir material.
Statistical analyses. Fully quantitative time course data were analyzed
by Friedman’s two-way analysis of variance (ANOVA) by ranks, followed
by all-pairwise comparisons (with P adjusted for multiple testing) if the
significance of the omnibus test was0.05. Only animals with complete
data sets at all six time points were included in the Friedman analyses.
Where within-group pairwise analyses were significant over time, medi-
ans between the treatment group and the respective control group at the
equivalent time points were compared by the Mann-Whitney U test with
exact significance. Fisher’s exact test was used to analyze both the frequen-
cies of viable and dead adult worms (both sexes combined) at the end of
each experiment and the distributions of endobacterial density scores at 0,
24, and 36 weeks posttreatment start (wpt) in experiment 2. All analyses
were performed with IBM SPSS Statistics v. 20 (IBM Corporation, Ar-
monk, NY, USA), and differences were considered to be statistically sig-
nificant at a critical probability of0.05.
RESULTS
Effects onnodule diameter and adultwormrecovery.The objec-
tive of experiment 1 was to determine the simplest OXY regimen
with partial adulticidal effects in order to facilitate the detection of
modified efficacy when RIF was added in combination. Marked
declines in nodule diameter were apparent in all three of the OXY-
treated groups, although this became statistically significant at an
earlier stage (36 wpt) in the PIR and OXY6 groups than in the
OXY3-1 group (where 1 indicates experiment 1) (Fig. 1a). How-
ever, at the end of the experiment, only the PIR and OXY3-1
groups exhibited reduced median nodule diameters relative to
those of the CON-1 group (Fig. 1a). Notably, one (OXY3-1,
OXY6) or two (PIR) nodules per group had resolved completely at
55 wpt and were assigned a diameter of 0. For experiment 2, effects
on nodule diameter were less pronounced than in the first exper-
iment, with only the OXY3-2 group displaying a significant reduc-
tion in nodule diameter at 24 wpt compared with intragroup base-
FIG 1 Nodule diameters (medians and ranges) in Onchocerca ochengi-infected cattle treated with oxytetracycline delivered once monthly for 6 months (PIR; n
5), twice weekly for 3 weeks (OXY3-1; n 6), or twice weekly for 6 weeks (OXY6; n 4) (a) and with rifampin alone twice weekly for 3 weeks (RIF3; n 6),
rifampin and oxytetracycline twice weekly for 3 weeks (COM; n 6), or oxytetracycline alone twice weekly for 3 weeks (OXY3-2; n 6) (b). Within groups,
medians at time points annotated with different letters are significantly different at a P of 0.05 (lowercase letters) or a P of 0.01 (uppercase letters) by
Friedman’s two-way ANOVA by ranks. Between groups, medians at time points annotated with an asterisk are significantly different from medians for the control
group (P 0.05 by the Mann-Whitney U test).
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line data and CON-2 data at the equivalent time point (Fig. 1b). In
addition, this reduction was not maintained at a statistically sig-
nificant level at 36 and 52 wpt (Fig. 1b).
The marked adulticidal effect of the PIR treatment was con-
firmed by analysis of adult worm recovery and viability at the end
of experiment 1 (Table 2). This regimen induced a 75% reduction
in the final yield of viable adult female worms relative to that of the
CON-1 group, and no adult male worms were recovered; the com-
bined effect on both sexes was statistically significant (P 0.023).
For the shorter OXY regimens, the reduction in the recovery of
female worms was 63% at 55 wpt, and no male worms were ob-
tained from OXY6 nodules at this time point (Table 2). However,
the decrease in total adult worm recovery was not statistically sig-
nificant for the OXY3-1 and OXY6 groups, although a strong
trend was apparent for the latter (P 0.052). In accordance with
the nodule diameter data, significant adulticidal effects were not
apparent in experiment 2 for the RIF3 and COM groups (Table 2).
In contrast, the OXY3-2 regimen achieved reductions in loads of
viable female and male worms of 50% and 83%, respectively,
which was statistically significant in aggregate (P 0.036).
Effects on microfilarial density. In experiment 1, statistically
significant declines in Mf density of 2 to 3 logs were observed with
all three OXY regimens by 36 to 55 wpt, although complete elim-
ination of Mf was achieved only in the OXY6 group (Fig. 2a). The
reductions in Mf load were also statistically significant compared
with loads in the absence of treatment (CON-1) for the PIR group
at 36 wpt and for the OXY3-1 and OXY6 regimens at 55 wpt
(Fig. 2a). The lack of adulticidal effects exhibited by the RIF3 and
COM groups in experiment 2 were also reflected by a limited
impact on Mf, although a transient but statistically significant re-
duction in Mf density of1 log was apparent in the COM group
at 24 and 36 wpt (Fig. 2b). Conversely, the efficacy of the OXY3-2
regimen against adult worms was mirrored by an2-log within-
group decline in Mf density at 36 and 52 wpt; moreover, this was
statistically significant relative to Mf densities in the CON-2 group
at these time points (Fig. 2b).
Effects on Wolbachia density in adult worms. To determine
whether the poor efficacy of the RIF3 and COM regimens in ex-
periment 2 was associated with failure to clear Wolbachia popula-
tions within adult worms, we stained histological sections of bo-
vine nodules from 0, 24, and 36 wpt with an anti-Wolbachia
surface protein antibody. In O. ochengi and in filarial nematodes
of medical importance, including O. volvulus, the distribution of
Wolbachia conforms to a highly predictable pattern, with high
densities of endobacteria in the somatic hypodermal cords of both
adult males and females, whereas only females contain symbionts
in their gonads and, consequently, in developing embryos. Thus,
sections from CON-2 nodules showed intense, punctate staining
of the bacteria in the hypodermal cords of the worms and finer
stippling of the symbionts in the ovaries and intrauterine embry-
onic stages (Fig. 3a to c). In the RIF3 and COM groups, extensive
Wolbachia populations remained clearly visible across the time
course in both the hypodermal cords and the female reproductive
tracts (Fig. 3d to f and j to l, respectively); however, oocytes and
FIG 2 Microfilarial densities per 100 mg skin (medians and ranges, plotted on a log x 1-transformed scale) in Onchocerca ochengi-infected cattle treated with
oxytetracycline delivered once monthly for 6 months (PIR; n 5), twice weekly for 3 weeks (OXY3-1; n 6), or twice weekly for 6 weeks (OXY6; n 4) (a) and
with rifampin alone twice weekly for 3 weeks (RIF3; n 6), rifampin and oxytetracycline twice weekly for 3 weeks (COM; n 6), or oxytetracycline alone twice
weekly for 3 weeks (OXY3-2; n 6) (b). (a) Control animals (CON-1; n 5) received no treatment; (b) control animals (CON-2; n 5) received DMSO solvent
at a dose equivalent to that of the RIF3 and COM groups. Within groups, medians at time points annotated with different letters are significantly different at a
P of 0.05 by Friedman’s two-way ANOVA by ranks. Between groups, medians at time points annotated with asterisks are significantly different from those of
the control group (P 0.05 [*] or P 0.01 [**] by the Mann-Whitney U test).
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morulae tended to exhibit an abnormal, granular morphology at
36 wpt (Fig. 3f and l). The OXY3-2 regimen displayed the most
pronounced effects, with complete loss of Wolbachia staining
from the hypodermal cords in most sections and a marked reduc-
tion in uterine contents at 24 wpt, although endobacteria re-
mained detectable occasionally in degenerated oocytes (Fig. 3 h).
Importantly, by 36 wpt, almost-complete resolution of fragments
from dead worms could be observed (Fig. 3i).
These immunohistochemical observations of Wolbachia den-
sity were verified using a semiquantitative scoring system, which
revealed a statistically significant reduction in numbers of nodules
containing 50% endobacterium-positive hypodermal cords
within worm sections in the OXY3-2 group at both 24 (P 0.015)
and 36 (P 0.002) wpt (Fig. 4a). This was not the case with either
the RIF3 or the COM regimen, although a strong but nonsignifi-
cant (P  0.061) pattern of reduced endobacterial density was
observed at 36 wpt for the latter (Fig. 4a). In contrast, no statisti-
cally significant changes in Wolbachia staining within the female
worm reproductive tract were apparent throughout experiment 2
(Fig. 4b).
FIG 3 Localization of Wolbachia endobacteria in nodule sections from Onchocerca ochengi-infected cattle treated with DMSO solvent only (a, b, c), rifampin
alone twice weekly for 3 weeks (d, e, f), oxytetracycline alone twice weekly for 3 weeks (g, h, i), or rifampin and oxytetracycline twice weekly for 3 weeks (j, k, l)
at 0 (a, d, g, j), 24 (b, e, h, k), and 36 (c, f, i, l) weeks posttreatment start. Yellow arrows, intrauterine microfilariae; filled black arrowheads, Wolbachia organisms
in the hypodermal cords; white arrows, morulae; open black arrowheads, Wolbachia organisms in the female reproductive tract; black arrow, migrating
microfilaria; open yellow arrowhead, partially resorbed worm section. Sections were probed with an anti-Wolbachia surface protein polyclonal antibody, which
was visualized using 3,3=-diaminobenzidine precipitate, and counterstained with Giemsa stain. Bars, 50 m.
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RIF concentrations in bovine plasma and skin. To establish if
the poor efficacy of the RIF3 regimen could be explained by the
pharmacokinetics of this drug in cattle, we measured RIF concen-
trations in the plasma and skin of four animals treated with a
regimen identical to that administered to the RIF3 group. The
mean maximum concentration of RIF in plasma (Cmax) was28
g/ml and was maintained above the MIC for Wolbachia (24, 25)
for at least 24 h (Fig. 5a) but was no longer detectable by 48 h.
Similarly, RIF concentrations in skin, although approximately 10-
fold lower than those achieved in plasma, remained above the
MIC for24 h (Fig. 5b) but were below the limit of quantification
by 48 h.
DISCUSSION
The greatest barrier to the implementation of antibiotic chemo-
therapy for onchocerciasis has been the duration of the regimen
required for permanent sterilization of female worms or potent
adulticidal effects (23). Although DOX is clearly more efficacious
than ivermectin, the latter can suppress Mf densities (and thus,
disease manifestations) for up to 1 year following a single dose of
150g/kg, which makes it highly amenable to MDA programs (4).
In a clinical trial in a area of Cameroon where loiasis is endemic,
community-wide distribution of daily DOX therapy for 6 weeks
was accompanied by very high rates of compliance (22), but to
date, this has not resulted in wider application of DOX by APOC.
A lack of contraindication in children, coupled with RIF’s bac-
tericidal mode of action, has led it to be mooted as a more favor-
FIG4 Endobacterial density scores in Onchocerca ochengi hypodermal cords (a) or O. ochengi female reproductive tracts (b) in nodular histological sections from
infected cattle treated with DMSO solvent only (CON-2), rifampin alone twice weekly for 3 weeks (RIF3), rifampin and oxytetracycline twice weekly for 3 weeks
(COM), or oxytetracycline alone twice weekly for 3 weeks (OXY3-2) at 0, 24, and 36 weeks posttreatment start. Wolbachia staining in worm sections across the
entirety of each slide was semiquantified on a 3-point scale, as follows: 0, no visible bacteria; 1, sparse bacteria (50% of worm sections were positive); and 2,
profuse bacterial (50% of worm sections were positive). Note that data were not available for two OXY3-2 nodules, three COM nodules, and two RIF3 nodules
due to complete resorption of the worms (n 5) or misidentification of nodules caused by Demodex bovis (n 2).
FIG 5 Rifampin concentration-time profiles (means 	 standard deviations;
n 4) in bovine plasma (a) and bovine skin (b) following a single intravenous
injection at 10 mg/kg.
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able alternative to DOX in this context. However, RIF alone has
not proved to be strongly adulticidal in human trials, even if ad-
ministered daily for 4 weeks (30). In the current study, we rea-
soned that a combination of a tetracycline and RIF might be more
efficacious than either drug alone, as inhibition of both translation
(by the former) and RNA synthesis (by the latter) is expected to
induce synergistic effects. In addition, an earlier in vivo trial in the
rodent filarial model Litomosoides sigmodontis revealed enhanced
efficacy (prophylaxis, growth retardation, and embryostasis) for
DOX and RIF duotherapy for 14 days compared with the efficacy
of DOX monotherapy for 21 days (27). Moreover, an50% adul-
ticidal effect of 14-day duotherapy was observed in a human clin-
ical trial against Wuchereria bancrofti (38), a pathogen responsible
for lymphatic filariasis which also harbors Wolbachia. Surpris-
ingly, not only did our data fail to support the superiority of duo-
therapy, they also consistently reflected an impaired efficacy of the
combination relative to that of OXY alone. Thus, in experiment 2,
only OXY monotherapy attained significant reductions in Mf
loads, Wolbachia densities in the hypodermal cords, and the re-
covery of viable adult worms at the end of the trial.
Unfortunately, no commercial formulation of RIF licensed for
administration to ruminants is available worldwide. For welfare
reasons, we were unable to deliver RIF on a daily schedule due to
the large volumes of intravenous solution required, and accord-
ingly, drug concentrations fell below the MIC for Wolbachia
(0.0625 mg/liter [24, 25]) between 24 and 48 h. As RIF levels are
reduced by 20 to 25% by heat inactivation of plasma (37), the
concentrations determined in our bovine samples may have been
underestimated; nevertheless, it is likely that our regimen
achieved a therapeutic dose in skin for only two periods slightly in
excess of 24 h each week. Although this drug is generally consid-
ered to have good penetrance and residual activity in tissue, we are
not aware of other studies that have quantified RIF in skin. How-
ever, in a case of human RIF overdose, discoloration of skin re-
solved after 24 h, while urine and tears remained red-orange for
several days (39). Possibly, the subcutaneous location of human
nodules renders O. volvulus more susceptible to RIF than is O.
ochengi, especially as the drug is photosensitive (40). Conversely,
the long-acting formulation of OXY is known to achieve thera-
peutic levels for 3 to 5 days following a single intramuscular injec-
tion (41); hence, a twice-weekly schedule is effectively a continu-
ous regimen. While these considerations provide a superficial
explanation for the inefficacy of RIF monotherapy relative to OXY
monotherapy, intermittent regimens of OXY are generally supe-
rior to continuous administration in this system, as observed in
the current study with PIR and in several previous trials (18, 36,
42). Moreover, the relatively rapid clearance of RIF in cattle does
not explain why RIF-OXY duotherapy is apparently less effica-
cious than OXY alone.
In monogastric species, daily therapy with RIF is generally well
tolerated, and in vivo trials against L. sigmodontis and Brugia pah-
angi in rodents used doses of 50 mg/kg (27) and up to 100 mg/kg
(28), respectively. However, even clinical trials of “higher-dose”
RIF for tuberculosis in humans have not exceeded regimens of 20
mg/kg daily (43), which raises questions regarding the interpreta-
tion of the rodent studies. Notably, 20 doses of RIF monotherapy
at 100 mg/kg failed to achieve a significant adulticidal effect on B.
pahangi transplanted into jirds (28), whereas the potent antifi-
larial properties of a 14-day combination regimen of RIF and
DOX against L. sigmodontis in mice were manifested when che-
motherapy was initiated simultaneously with infection using
third-stage larvae (27). Thus, these effects against L. sigmodontis
were not genuinely adulticidal. Combinations of RIF and DOX
have rarely been used in human clinical trials for other conditions,
although in the case of scrub typhus (caused by another member
of the Rickettsiales, Orientia tsutsugamushi), duotherapy was inef-
ficacious compared to either drug alone (44). The reasons for this
failure were not determined, but in duotherapy for brucellosis,
pharmacokinetic interference between DOX and RIF has been
reported. Hence, plasma levels of DOX were reduced by 50% in
brucellosis patients exhibiting metabolic induction of hepatic
microsomal enzymes (45), while in a larger study, a statistically
significant inverse correlation between DOX and RIF plasma
concentrations was apparent, which resulted in two cases of
therapeutic failure or relapse (46). Moreover, there was a trend for
DOX levels to be lower in brucellosis patients also receiving RIF
who had a “rapid acetylator” N-acetyltransferase-2 genotype (46).
Although, to the best of our knowledge, no studies on liver func-
tion following RIF therapy have been performed on ruminants, a
detrimental effect on OXY pharmacokinetics caused by metabolic
induction is a plausible explanation for the poor efficacy of duo-
therapy in our study.
In conclusion, despite promising early indications in vitro and
in small-animal studies in vivo, RIF (whether alone or in combi-
nation with a tetracycline) may not represent the breakthrough in
adulticidal therapy for onchocerciasis that was hoped. In addition
to having potentially unfavorable pharmacokinetic interactions
with tetracyclines, RIF remains of critical importance in tubercu-
losis control in the countries where onchocerciasis is endemic
(47), rendering RIF MDA for onchocerciasis extremely unlikely.
In this context, the recent discovery that Wolbachia is highly sus-
ceptible to another RNA polymerase inhibitor, corallopyronin A,
which lacks activity against mycobacteria, is timely (48). More-
over, the successful chemical synthesis of this natural product (49)
provides an avenue for its clinical development and ultimate ap-
plication to human filarial diseases (50).
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